Regeneron Reports Interim Data from P-III (C-POST) Trial of Libtayo Adjuvant to Treat High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)
Shots:
- The P-III (C-POST) trial assessed Libtayo adj. (n=205; 350mg, IV, Q3W for first 12wks. followed by 700mg, IV, Q6W for 36wks.) vs PBO (n=204) to treat high-risk CSCC patients (N=415) for ~48wks.
- Study met its first prespecified interim analysis, showing 68% reduced disease occurrence & death risk at 24mos. median follow-up, with additional follow-up, incl. OS analysis (2EP) underway; AEs occurred in 91% vs 89% (grade ≥3 AEs: 24% vs 14%). The US FDA’s filing is expected in H1'25
- Libtayo is a fully human mAb developed using Regeneron's VelocImmune tech that inhibits the PD-1 pathway in cancer cells to suppress T-cell activation for treating advanced BCC, CSCC, NSCLC & cervical cancer
Ref: Regeneron | Image: Regeneron
Related News:- Regeneron Reports Results from P-II (ROXI-VTE-I and ROXI-VTE-II) Trials of REGN7508 and REGN9933 for Venous Thromboembolism
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
